EPCAM and colorectal cancer: The weak correlation between the leukocyte counts in the EpCAM-enriched samples and the leukocyte counts from the available complete blood counts (Table S1) rejects a plausible explanation that the leukocyte carryover reflects the total leukocyte count of patients, with the latter known to be associated with patients’ clinical outcome in bladder, prostate, and non-small-cell lung cancers [44,45,46,47], as well as in colorectal cancer (Table 1).